<DOC>
	<DOCNO>NCT00165685</DOCNO>
	<brief_summary>To investigate efficacy safety KES524 patient obesity ( visceral fat obesity type 2 diabetes dyslipidemia ) , 52-week , double-blind , placebo-controlled comparative study conduct . This study aim examine superiority KES524 placebo employ change percent change body weight ( primary endpoint ) change proportion subject achieve ≧ 5 % weight reduction , BMI , waist circumference , visceral fat area , subcutaneous fat area , V/S ratio abdominal CT scan , HbA1c , TG HDL-C ( secondary endpoint ) .</brief_summary>
	<brief_title>A Comparative Study KES524 Patients With Obesity Disease</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Sibutramine</mesh_term>
	<criteria>Patients ≧25 kg/m2 BMI start observation period Patients visceral fat area ≧100 cm2 measure abdominal CT scan Patients follow two health impairment : 1 . Patients previously diagnose type 2 diabetes HbA1c ≧6.1 % &lt; 9.0 % start observation period 2 . Patients ≧150 mg/dL triglyceride ( TG ) , and/or &lt; 40 mg/dL highdensity lipoprotein cholesterol ( HDLC ) serum lipid parameter dyslipidemic index start observation period Patients continuously receive diet therapy 8 week longer start observation period Patients receive antidiabetic ( 12 week ) , antihyperlipidemics ( 4 week ) and/or antihypertensive ( 4 week ) drug . If use , receive consistent dosage administration begin 4 week ( 12 week antidiabetic ) start observation period Patients ambulatory treatment age ≧20 year &lt; 65 year time obtain informed consent Patients give full explanation study objective content give write informed consent Patients pulse rate ≧100/min observation period Patients systolic blood pressure ≧160 mmHg and/or diastolic blood pressure ≧100 mmHg observation period Patients body weight loss ≧3 % compare start observation period , body mass index ( BMI ) reduce &lt; 25 kg/m2 observation period Patients receive insulin within 12 week start observation period Patients present illness past history severe eat disorder ( e.g. , anorexia nervosa bulimia nervosa ) Patients present illness past history drug allergy severe allergic disease ( ) Patients present illness past history follow disorder : Coronary artery disease ( myocardial infarction , angina ) , heart failure Serious diseases cardiovascular ( severe tachycardiac heart failure ) , renal ( renal failure ) , hepatic ( severe hepatitis , cirrhosis ) , pancreatic ( severe pancreatitis ) , psychotic ( severe depression , schizophrenia , alcohol addict , drug addict ) disorder Pregnant lactate woman , woman intend become pregnant study period Patients previously participate treated another clinical study KES524 Patients receive another study drug within 24 week start observation period study Patients judge ineligible study entry investigator subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>